

# Tasanee Braithwaite

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3844355/publications.pdf>

Version: 2024-02-01

41  
papers

20,199  
citations

394421

19  
h-index

315739

38  
g-index

41  
all docs

41  
docs citations

41  
times ranked

32366  
citing authors

#	ARTICLE	IF	CITATIONS
1	Metformin and risk of age-related macular degeneration in individuals with type 2 diabetes: a retrospective cohort study. <i>British Journal of Ophthalmology</i> , 2023, 107, 980-986.	3.9	12
2	Capturing the experiences of patients with inherited optic neuropathies: a systematic review of patient-reported outcome measures (PROMs) and qualitative studies. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2022, , 1.	1.9	2
3	The economics of vision impairment and its leading causes: A systematic review. <i>EClinicalMedicine</i> , 2022, 46, 101354.	7.1	24
4	212â€¦ Preventing blindness for patients with optic disc swelling: improving care using transformative new technology. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A74.3-A74.	1.9	1
5	Trends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the Global Burden of Disease Study. <i>The Lancet Global Health</i> , 2021, 9, e130-e143.	6.3	500
6	The Lancet Global Health Commission on Global Eye Health: vision beyond 2020. <i>The Lancet Global Health</i> , 2021, 9, e489-e551.	6.3	549
7	Epidemiology of Scleritis in the United Kingdom From 1997 to 2018: Populationâ€Based Analysis of 11 Million Patients and Association Between Scleritis and Infectious and Immuneâ€Mediated Inflammatory Disease. <i>Arthritis and Rheumatology</i> , 2021, 73, 1267-1276.	5.6	25
8	Development and application of the ocular immune-mediated inflammatory diseases ontology enhanced with synonyms from online patient support forum conversation. <i>Computers in Biology and Medicine</i> , 2021, 135, 104542.	7.0	2
9	Bilateral anterior non-necrotising scleritis, anterior uveitis, and unilateral facial nerve palsy in paediatric inflammatory multisystem syndrome temporally associated with COVID-19. <i>Lancet Rheumatology, The</i> , 2021, 3, e818.	3.9	9
10	National Eye Survey of Trinidad and Tobago (NESTT): prevalence, causes and risk factors for presenting vision impairment in adults over 40 years. <i>British Journal of Ophthalmology</i> , 2020, 104, 74-80.	3.9	15
11	Prevalence and causes of vision loss in East Asia in 2015: magnitude, temporal trends and projections. <i>British Journal of Ophthalmology</i> , 2020, 104, 616-622.	3.9	36
12	Instrument-based Tests for Measuring Anterior Chamber Cells in Uveitis: A Systematic Review. <i>Ocular Immunology and Inflammation</i> , 2020, 28, 898-907.	1.8	16
13	Case for a new corticosteroid treatment trial in optic neuritis: review of updated evidence. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 9-14.	1.9	22
14	Selfâ€reported visual difficulties in Europe and related factors: a European populationâ€based crossâ€sectional survey. <i>Acta Ophthalmologica</i> , 2020, 99, 559-568.	1.1	3
15	Trends in Optic Neuritis Incidence and Prevalence in the UK and Association With Systemic and Neurologic Disease. <i>JAMA Neurology</i> , 2020, 77, 1514.	9.0	45
16	Implications of the artificial intelligence extensions to the guidelines for consolidated standards of reporting trials and for standard protocol item recommendations for interventional trials (the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 137		
17	Estimating the global cost of vision impairment and its major causes: protocol for a systematic review. <i>BMJ Open</i> , 2020, 10, e036689.	1.9	11
18	Vision Loss from Atypical Optic Neuritis: Patient and Physician Perspectives. <i>Ophthalmology and Therapy</i> , 2020, 9, 215-220.	2.3	6

#	ARTICLE	IF	CITATIONS
19	Prevalence and causes of vision loss in sub-Saharan Africa in 2015: magnitude, temporal trends and projections. <i>British Journal of Ophthalmology</i> , 2020, 104, 1658-1668.	3.9	32
20	Cochrane corner: why we still don't know whether anti-TNF biologic therapies impact uveitic macular oedema. <i>Eye</i> , 2019, 33, 1830-1832.	2.1	4
21	&lt;p&gt;The use of patient-reported outcome research in modern ophthalmology: impact on clinical trials and routine clinical practice&lt;/p&gt;. <i>Patient Related Outcome Measures</i> , 2019, Volume 10, 9-24.	1.2	86
22	Impact of Vision Loss on Health-Related Quality of Life in Trinidad and Tobago. <i>Ophthalmology</i> , 2019, 126, 1055-1058.	5.2	4
23	Prevalence and causes of vision loss in Latin America and the Caribbean in 2015: magnitude, temporal trends and projections. <i>British Journal of Ophthalmology</i> , 2019, 103, 885-893.	3.9	16
24	Health system dynamics analysis of eyecare services in Trinidad and Tobago and progress towards Vision 2020 Goals. <i>Health Policy and Planning</i> , 2018, 33, 70-84.	2.7	10
25	Multiple deprivation, vision loss, and ophthalmic disease in adults: global perspectives. <i>Survey of Ophthalmology</i> , 2018, 63, 406-436.	4.0	30
26	The National Eye Survey of Trinidad and Tobago (NESTT): Rationale, Objectives and Methodology. <i>Ophthalmic Epidemiology</i> , 2017, 24, 116-129.	1.7	6
27	Does blindness count? Disability weights for vision loss. <i>Clinical and Experimental Ophthalmology</i> , 2017, 45, 217-220.	2.6	9
28	Global causes of blindness and distance vision impairment 1990â€“2020: a systematic review and meta-analysis. <i>The Lancet Global Health</i> , 2017, 5, e1221-e1234.	6.3	2,053
29	Magnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: a systematic review and meta-analysis. <i>The Lancet Global Health</i> , 2017, 5, e888-e897.	6.3	1,443
30	Addressing ethical challenges in the Genetics Substudy of the National Eye Survey of Trinidad and Tobago (GSNESTT). <i>Applied &amp; Translational Genomics</i> , 2016, 9, 6-14.	2.1	6
31	Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion. <i>The Cochrane Library</i> , 2014, 2014, CD007325.	2.8	83
32	Diagnostic features of the autoimmune retinopathies. <i>Autoimmunity Reviews</i> , 2014, 13, 534-538.	5.8	44
33	UK health performance: findings of the Global Burden of Disease Study 2010. <i>Lancet</i> , 2013, 381, 997-1020.	13.7	479
34	New Systematic Review Methodology for Visual Impairment and Blindness for the 2010 Global Burden of Disease Study. <i>Ophthalmic Epidemiology</i> , 2013, 20, 33-39.	1.7	64
35	Subacute bilateral vision loss resulting from dengue maculopathy. <i>BMJ Case Reports</i> , 2013, 2013, bcr2013200542-bcr2013200542.	0.5	1
36	Autoimmune Retinopathy. <i>Ophthalmologica</i> , 2012, 228, 131-142.	1.9	75

#	ARTICLE	IF	CITATIONS
37	Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2129-2143.	13.7	1,013
38	Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990â€“2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2197-2223.	13.7	7,061
39	Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990â€“2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2163-2196.	13.7	6,376
40	Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion. , 2010, , CD007325.		24
41	Chronic optic disc swelling overlooked in a diabetic patient with a devastating outcome. BMJ Case Reports, 2010, 2010, bcr0620091975-bcr0620091975.	0.5	0